Reply to the Letter to the Editor on “Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients”, by I. Cohen Ann Oncol 2005; 16: 1399

Authors: Paridaens, R.¹; Morales, L.¹; Neven, P.²; On behalf of all co-authors of the original article,

Source: Annals of Oncology, Volume 16, Number 8, August 2005 , pp. 1402-1403(2)

Publisher: Oxford University Press

Keywords: bone disease; bisphosphonates; macrophage inflammatory protein-1 alpha (MIP-1); multiple myeloma; osteoprotegerin; receptor activator of nuclear factor-kappa B ligand (RANKL)

Document Type: Research article

DOI: http://dx.doi.org/10.1093/annonc/mdi237

Affiliations: 1: Departments of Medical Oncology and 2: Multidisciplinary Breast Center, University Hospital Gasthuisberg KU Leuven, Herestraat 49, 3000 Leuven, Belgium

Publication date: 2005-08-01

• Annals of Oncology is a multidisciplinary journal that publishes articles addressing medical oncology, surgery, radiotherapy, paediatric oncology, basic research and the comprehensive management of patients with malignant diseases.

• In this: publication
• By this: publisher
• In this Subject: Oncology
• By this author: Paridaens, R. ;  Morales, L. ;  Neven, P. ;  On behalf of all co-authors of the original article,

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers